Clinical trial
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of…
NCT00165880 · Eisai Limited, Industry · Terminated
Key facts
| NCT number | NCT00165880 |
|---|---|
| Title | An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine |
| Official title | An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy |
| Lead sponsor | Eisai Limited, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | E7070 |
| Enrollment | 62 |
| Start date | Dec 1, 2004 |
| Completion | Sep 1, 2007 |
| First posted | Sep 14, 2005 |
| Last update posted | Jul 1, 2014 |
| Countries | Germany, Italy, Russia, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: